title: Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002.
abstract: Few studies have addressed longer-term survival for breast cancer in European women. We have made predictions of 10-year survival for European women diagnosed with breast cancer in 2000-2002. Data for 114,312 adult women (15-99 years) diagnosed with a first primary malignant cancer of the breast during 2000-2002 were collected in the EUROCARE-4 study from 24 population-based cancer registries in 14 European countries. We estimated relative survival at 1, 5, and 10 years after diagnosis for women who were alive at some point during 2000-2002, using the period approach. We also estimated 10-year survival conditional on survival to 1 and 5 years after diagnosis. Ten-year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten-year survival conditional on survival for 1 year was 2-6% higher than 10-year survival in all European regions, and geographic differences were smaller. Ten-year survival for women who survived at least 5 years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50-69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10-year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population-based survival, which provides vital information for improving breast cancer control.
authors.affiliation: Analytical Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. claudia.allemani@lshtm.ac.uk
authors.forename: Claudia
authors.initials: C
authors.lastname: Allemani
authors.forename: Pamela
authors.initials: P
authors.lastname: Minicozzi
authors.forename: Franco
authors.initials: F
authors.lastname: Berrino
authors.forename: Esther
authors.initials: E
authors.lastname: Bastiaannet
authors.forename: Anna
authors.initials: A
authors.lastname: Gavin
authors.forename: Jaume
authors.initials: J
authors.lastname: Galceran
authors.forename: Alberto
authors.initials: A
authors.lastname: Ameijide
authors.forename: Sabine
authors.initials: S
authors.lastname: Siesling
authors.forename: Lucia
authors.initials: L
authors.lastname: Mangone
authors.forename: Eva
authors.initials: E
authors.lastname: Ardanaz
authors.forename: Guy
authors.initials: G
authors.lastname: Hédelin
authors.forename: Antonio
authors.initials: A
authors.lastname: Mateos
authors.forename: Andrea
authors.initials: A
authors.lastname: Micheli
authors.forename: Milena
authors.initials: M
authors.lastname: Sant
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis / Q000401:mortality*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D012042:Registries; D016019:Survival Analysis; D015996:Survival Rate